QIAGEN N.V. (QIA.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:QIA - NL0015002CX3 - Common Stock
QIA.DE Key Statistics, Chart & Performance
The current stock price of QIA.DE is 40.4 EUR. In the past month the price increased by 3.98%. In the past year, price decreased by -3.21%.
QIA.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| DIM.PA | SARTORIUS STEDIM BIOTECH | 48.19 | 20.22B | ||
| 56S1.DE | SARTORIUS STEDIM BIOTECH | 48.12 | 20.19B | ||
| SRT3.DE | SARTORIUS AG-VORZUG | 54.45 | 18.59B | ||
| SRT.DE | SARTORIUS AG | 42.41 | 14.48B | ||
| 1SXP.DE | SCHOTT PHARMA AG& CO KGAA | 19.38 | 2.83B | ||
| EVT.DE | EVOTEC SE | N/A | 2.00B | ||
| GXI.DE | GERRESHEIMER AG | 7.05 | 898.04M | ||
| FF.MI | FINE FOODS & PHARMACEUTICALS | 10.61 | 208.25M |
Related stock screener links
About QIA.DE
Company Profile
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,700 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Company Info
QIAGEN N.V.
Hulsterweg 82
Venlo LIMBURG NL
Employees: 5232
Phone: 31773556600
QIAGEN N.V. / QIA.DE FAQ
What does QIA do?
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,700 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
What is the stock price of QIAGEN N.V. today?
The current stock price of QIA.DE is 40.4 EUR. The price decreased by -1.55% in the last trading session.
Does QIAGEN N.V. pay dividends?
QIAGEN N.V. (QIA.DE) has a dividend yield of 0.52%. The yearly dividend amount is currently 0.
What is the ChartMill rating of QIAGEN N.V. stock?
QIA.DE has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Where is QIAGEN N.V. (QIA.DE) stock traded?
QIA.DE stock is listed on the Frankfurt Stock Exchange exchange.
What is the employee count for QIA stock?
QIAGEN N.V. (QIA.DE) currently has 5232 employees.
Can you provide the market cap for QIAGEN N.V.?
QIAGEN N.V. (QIA.DE) has a market capitalization of 8.76B EUR. This makes QIA.DE a Mid Cap stock.
QIA.DE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to QIA.DE. When comparing the yearly performance of all stocks, QIA.DE is a bad performer in the overall market: 70.66% of all stocks are doing better.
QIA.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to QIA.DE. QIA.DE scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
QIA.DE Financial Highlights
Over the last trailing twelve months QIA.DE reported a non-GAAP Earnings per Share(EPS) of 2.04. The EPS increased by 9.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 19.58% | ||
| ROA | 6.19% | ||
| ROE | 11.11% | ||
| Debt/Equity | 0.45 |
QIA.DE Forecast & Estimates
24 analysts have analysed QIA.DE and the average price target is 44.49 EUR. This implies a price increase of 10.13% is expected in the next year compared to the current price of 40.4.
For the next year, analysts expect an EPS growth of 8.55% and a revenue growth 5.25% for QIA.DE